版本:
中国

BRIEF-Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial

May 17 Omeros Corp

* Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial

* Omeros Corp - additional positive results support rapid advancement to phase 3 trial

* Omeros Corp - consistent with all other OMS721 clinical trials, no significant safety concerns have been observed

* Omeros Corp - most commonly reported adverse events in trial are fatigue and anemia Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐